BILL ANALYSIS Ó
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
AB 1668 (Calderon) - Investigational drugs, biological products,
and devices
-----------------------------------------------------------------
| |
| |
| |
-----------------------------------------------------------------
|--------------------------------+--------------------------------|
| | |
|Version: March 7, 2016 |Policy Vote: HEALTH 9 - 0, B., |
| | P. & E.D. 9 - 0 |
| | |
|--------------------------------+--------------------------------|
| | |
|Urgency: No |Mandate: No |
| | |
|--------------------------------+--------------------------------|
| | |
|Hearing Date: August 11, 2016 |Consultant: Brendan McCarthy |
| | |
-----------------------------------------------------------------
*********** ANALYSIS ADDENDUM - SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 11, 2016
Bill
Summary: AB 1668 would authorize the manufacturer of an
investigational drug to make an investigational drug available
to a patient, under certain circumstances.
Fiscal
Impact: One-time costs of $20,000 and ongoing costs of $10,000 per
year to review plan filings by the Department of Insurance
(Insurance Fund).
One-time costs of $380,000 in 2015-16 to respond to requests
AB 1668 (Calderon) Page 1 of
?
for information about prior independent medical review
decisions and ongoing costs of $210,000 per year to respond to
consumer complaints and requests for independent medical
review for access to investigational drugs by the Department
of Managed Health Care (Managed Care Fund).
Uncertain impact on state-funded CalPERS health care coverage
(General Fund and special funds). (See below.)
Author
Amendments: Make a clarifying change.
-- END --